Hereditary pancreatic cancer, especially associated with BRCA mutations, is responsive to platinum-containing regimens and/or poly (ADP-ribose) polymerase (PARP) inhibitors. The gene discussed is PARP1; the disease is familial pancreatic carcinoma.